

FORM PTO-1449/A and B (Modified)

APPLICATION NO.: 09/669,187

ATTY. DOCKET NO. G1039/2035

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JUN 14 2001

FILING DATE: September 25, 2000

APPLICANT: Krieg et al.

GROUP ART UNIT: 1646

EXAMINER: unknown

RECEIVED

JUN 19 2001

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

## FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
DB	B1	WIPO	WO98/40100	A1		09-17-1998	
DB	B2	WIPO	WO99/58118	A2		11-18-1999	
DB	B3	WIPO	WO99/61056	A2		12-02-1999	

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
DB	C14	LIPFORD GB et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. <i>Eur J Immunol.</i> 1997 Sep;27(9):2340- 4.		

EXAMINER

DATE CONSIDERED


Daniel Blehul

6/17/04

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and  
relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an  
earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided  
in the earlier application.]



<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 09/669,187		ATTY. DOCKET NO.: C1039.70035US00			
				FILING DATE: September 25, 2000		CONFIRMATION NO.: 2999			
				APPLICANT: Arthur M. Krieg					
				GROUP ART UNIT: 1642		EXAMINER: David J. Blanchard			
Sheet	1	of	1						

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

**FOREIGN PATENT DOCUMENTS**


Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
DB	B36	WO	00/54803	A2	Panacea Pharmaceuticals, LLC	09-21-2000	
DB	B37	WO	00/75304	A1	Aventis Pasteur	12-14-2000	Abstract

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)

EXAMINER <i>David J. Blanchard</i>	DATE CONSIDERED <i>6/17/04</i>
---------------------------------------	-----------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/669,187	ATTY. DOCKET NO.: C1039.70035US00
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		FILING DATE: September 25, 2000	CONFIRMATION NO.: 2999
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1642	EXAMINER: Blanchard, David J.
Sheet	1		

#### U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
DB	C97	GOUKASSIAN et al., "Topical DNA Oligonucleotide Therapy Reduces UV-induced Mutations and Photocarcinogenesis in Hairless Mice", <i>PNAS</i> , 101(11): 3933-3938, 2004.		

EXAMINER 	DATE CONSIDERED 6/17/04
--	-------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet 1 of 1

APPLICATION NO.: 09/669,187

ATTY. DOCKET NO.: C1039.70035US00

FILING DATE: September 25, 2000

CONFIRMATION NO.: 2999

APPLICANT: Krieg et al.

GROUP ART UNIT: 1642

EXAMINER: David J. Blanchard

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
DB	C97	BOHLE et al. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol. 1999 Jul;29(7):2344-53.		

EXAMINER <i>David J. Blanchard</i>	DATE CONSIDERED <i>6/17/04</i>
---------------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO-6349/A and B (Modified)

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICATION NO.: 09/669,187

ATTY. DOCKET NO.: C01039.70035.US

FILING DATE: September 25, 2000

CONFIRMATION NO.: 2999

APPLICANT: Arthur M. Krieg, et al.

GROUP ART UNIT: 1633

EXAMINER: James Martinell


Sheet 1 of 4

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
DB	A1	5,023,243		Tullis	06-11-1991
	A2	5,248,670		Draper , et al.	09-28-1993
	A3	5,268,365		Rudolph , et al.	12-07-1993
	A4	5,445,938		Hanai , et al.	08-29-1995
	A5	5,488,039		Masor , et al.	01-30-1996
	A6	5,491,088		Hellstrom , et al.	02-13-1996
	A7	5,492,899		Masor , et al.	02-20-1996
	A8	5,585,479		Hoke , et al.	12-17-1996
	A9	5,589,466		Felgner , et al.	12-31-1996
	A10	5,591,721		Agrawal , et al.	01-07-1997
	A11	5,602,109		Masor , et al.	02-11-1997
	A12	5,612,060		Alexander	03-18-1997
	A13	5,663,153		Hutcherson , et al.	09-02-1997
	A14	5,679,647		Carson , et al.	10-21-1997
	A15	5,700,590		Masor , et al.	12-23-1997
	A16	5,705,385		Bally , et al.	01-06-1998
	A17	5,723,130		Hancock , et al.	03-03-1998
	A18	5,723,335		Hutcherson , et al.	03-03-1998
	A19	5,756,097		Landucci , et al.	05-26-1998
	A20	5,780,448		Davis	07-14-1998
	A21	5,786,189		Locht , et al.	07-28-1998
	A22	5,804,566		Carson , et al.	09-08-1998
	A23	5,830,877		Carson , et al.	11-03-1998
	A24	5,837,243		Deo , et al.	11-17-1998
	A25	5,849,719		Carson , et al.	12-15-1998
	A26	5,965,542		Wasan , et al.	10-12-1999
	A27	5,976,567		Wheeler , et al.	11-02-1999
	A28	5,981,501		Wheeler , et al.	11-09-1999
	A29	5,985,847		Carson , et al.	11-16-1999
	A30	6,013,639		Peyman , et al.	01-11-2000
V	A31	6,027,726		Ansell	02-22-2000
	A32	6,110,745		Zhang, et al.	08-29-2000
	A33	6,174,872		Carson , et al.	01-16-2001
	A34	6,194,388	B1	Krieg, et al.	02-27-2001
	A35	6,207,646	B1	Krieg, et al.	03-27-2001
	A36	6,214,806	B1	Schwartz, et al.	04-10-2001
	A37	6,218,371	B1	Krieg, et al.	04-17-2001

*David B. Burt*

6/17/04



RECEIVED  
APR 9 2003  
TECH CENTER 18000000

DB	A38	6,239,116	B1	Krieg, et al.	05-29-2001
	A39	6,339,068	B1	Davis, et al.	01-15-2002
	A40	6,406,705	B1	Davis, et al.	06-18-2002
V	A41	6,429,199	B1	Krieg, et al.	08-06-2002
DB	A42	2002/0064515	A1	Davis, et al.	05-30-2002

#### FOREIGN PATENT DOCUMENTS


Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
DB	B4	EP	0 302 758	B1	New England Medical Center Hospitals, Inc.	03-16-1994	
	B5	EP	0 468 520	A2	Mitsui Toatsu Chemicals, Inc.	01-29-1992	
	B6	WO	91/12811	A1	Isis Pharmaceuticals, Inc., Et Al.	09-05-1991	
	B7	WO	92/03456	A1	Isis Pharmaceuticals, Inc.	03-05-1992	
	B8	WO	92/18522	A1	The Salk Institute For Biological Studies,	10-29-1992	
	B9	WO	92/21353	A1	Genta Incorporated	12-10-1992	
	B10	WO	94/19945	A1	Isis Pharmaceuticals, Inc.	09-15-1994	
	B11	WO	95/05853	A1	The Regents Of The University Of CA	03-02-1995	
	B12	WO	95/26204	A1	Isis Pharmaceuticals, Inc.	10-05-1995	
	B13	WO	96/02555	A1	The University Of Iowa Research Foundation	02-01-1996	
	B14	WO	96/13277	A1	The Regents Of The University Of CA	05-09-1996	
	B15	WO	96/14074	A1	The Regents Of The University Of CA	05-17-1996	
	B16	WO	96/24380	A1	ICN Pharmaceuticals, Inc.	08-15-1996	
	B17	WO	96/35782	A1	Applied Research Systems, et al..	11-14-1996	
	B18	WO	98/14210	A1	The Regents Of The University Of CA	04-09-1998	
	B19	WO	98/16247	A1	The Regents Of The University Of CA	04-23-1998	
	B20	WO	98/18810	A1	The University Of Iowa Research Foundation	05-07-1998	
	B21	WO	98/29430	A1	Tam	07-09-1998	
	B22	WO	98/51278	A2	Inex Pharmaceuticals Corporation	11-19-1998	
	B23	WO	98/55495	A2	Dynavax Technologies Corporation	12-10-1998	
	B24	WO	98/55609	A1	The Regents Of The University Of CA	12-10-1998	
	B25	WO	99/33493	A1	Inex Pharmaceuticals Corporation	07-08-1999	
	B26	WO	99/52549	A1	Smithkline Beecham Biologicals S.A.,	10-21-1999	
	B27	WO	99/62923	A2	Dynavax Technologies Corporation	12-09-1999	
	B28	WO	00/03683	A2	Inex Pharmaceuticals Corporation	01-27-2000	
	B29	WO	00/14217	A2	CPG Immunopharmaceuticals Gmbh	03-16-2000	
	B30	WO	00/16804	A1	Dynavax Technologies Corporation	03-30-2000	
	B31	WO	00/20039	A1	The Regents Of The University Of CA	04-13-2000	
	B32	WO	00/21556	A1	Dynavax Technologies Corporation	04-20-2000	
V	B33	WO	00/62787	A1	The Regents Of The University Of CA	10-26-2000	
	B34	WO	01/02007	A1	The Regents Of The University Of CA	01-11-2001	
DB	B35	WO	01/12223	A2	Dynavax Technologies Corporation	02-22-2001	

#### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
---------------------	---------	---	-------------------

679747.1 *Daniel Bluh*


6/17/04



C15	AGRAWAL, et al., <i>Clin. Pharmacokinet</i> , 28(1):7-16, 1995		
C16	AGRAWAL, <i>Tibtech</i> , 14:376-387, 1996		
C17	ARKWRIGHT, et al. <i>J Allerg Clin Immunol</i> . 107:531-4, 2001		
C18	AZAD, et al., <i>Antimicrobial Agents and Chemotherapy</i> , 37:1945-1954, (1993)		
C19	AZUMA, et al., <i>Kekkaku</i> , 67(9):625-631, (45-55) 1992		
C20	BALLAS, et al., <i>J Immunol</i> 157(5):1840-5, 1996		
C21	BATES, et al. <i>J Biol Chem</i> 274:26369-77, 1999		
C22	BENIMETSKAYA, et al. <i>Nucleic Acids Res.</i> 25:2648-2656, 1997		
C23	BISHOP, et al. <i>J. Biol. Chem.</i> 271:5698-5703, 1996		
C24	BLAXTER et al., <i>Mol. and Biochem. Parasitology</i> , 77:77-93		
C25	BRANDA et al., <i>Biochemical Pharmacology</i> , 45(10):2037-2043, 1993		
C26	BRANDA, et al., <i>J. Lab Clin Med</i> 128(3):329-38, 1996		
C27	BROIDE & RAZ <i>Int Arch Allerg &amp; Immunol</i> . 118:453-456, 1999		
C28	BRUNNER, et al., <i>J Immunol</i> . 165:6278-6286, 2000		
C29	BURGESS, et al., <i>Proc. Natl. Acad. Sci USA</i> 92(9):4051-5, 1995		
C30	CARTER, et al. <i>Int J Immunopharmacol</i> . 13:69-76, 1991		
C31	CHACE, et al., <i>Clinical Immunology and Immunopathology</i> , (1993), 68(3):327-332		
C32	CONSTANT, et al., <i>Annu. Rev. Immunol.</i> , 15:297-322, 1997		
C33	CONSTANT, et al., <i>Science</i> , 264:267-70, 1994		
C34	COWDERY, et al., <i>J Immunol</i> 156(12):4570-5, 15 1996		
C35	COWSERT, et al. <i>Antimicrobial Chemother.</i> 37:171-77, 1993		
C36	DAPIC, et al. <i>Proc. AACR</i> , pp. 42, March 2001		
C37	DIAMANTSTEIN, et al. <i>Euro J Immunol</i> . 8:896, 1978		
C38	ELKINS, et al. <i>J. Immunol</i> . 162:2291-2298, 1999		
C39	EWEL, et al., <i>Cancer Res.</i> , 52(11):3005-10, 1992		
C40	FUJIEDA, et al., <i>Anticancer Res.</i> , 12:1941-1946, 1992		
C41	GAO, et al., <i>Mol. Pharmacol.</i> (1992), 41, 223-229		
C42	GOLD, et al., <i>Annual Rev. Biochem.</i> 64:763-97, 1995.		
C43	HADDEN J et al., <i>JAMA</i> , (1992) 268:20:2964-2969		
C44	HADDEN J et al., <i>TIPS</i> , (1993), 141:169-174		
C45	HAHM, et al. <i>Int J. Immunopharmacol</i> . 16:217, 1994		
C46	HALPERN MD et al., <i>Cell Immunol</i> 167(1):72-8, 1996		
C47	HARRINGTON, et al. <i>Infection Immunity</i> 24:160, 1970		
C48	HARTMANN, et al. <i>Antisense Nucleic Acid Drug Dev</i> , 6:291, 1996		
C49	HATZFELD J., <i>J. Exp. Med.</i> , (1991) 174:925-929		
C50	HERTL, et al., <i>J. Invest. Dermatol.</i> , 104:813-818, 1995.		
C51	HORNER, et al. <i>Springer Semin Immunopathol</i> , 22(1-2):133-46, 2000		
C52	HORSPOOL, et al., <i>J. Immunol</i> , 160, 2706-2714, 1998		
C53	HUANG, et al., <i>Infection and Immunity</i> , 67(12):6257-6263 (1999)		
C54	HUGHES, et al. <i>Antisense Res Dev</i> 4:211-15, 1994		
C55	ISHIKAWA, et al., <i>J Immunol</i> 150(9):3713-27, 1993		
C56	IVERSEN, et al., <i>Antisense Research and Development</i> , (1994), 4:43-52		
C57	JAKOB, et al., <i>Int. Arch Allergy Immunol.</i> , 118(2-4):457-61, 1999		
C58	JAKOB, et al., <i>J. Immunol.</i> , 161(6):3042-9, 1998		
C59	JOHNSON, et al. <i>Immunopharmacol Infect Disease</i> , 291-301, 1987		
C60	KARLIN, et al., <i>J. of Virol.</i> , 2889-2897, 1994		
C61	KATAOKA, et al., <i>Jpn. J. Med. Sci. Bio.</i> , 43:171-189 (1990)		

DB  
Daniel B. B. B.

6/17/04



C62	KERN, et al. <i>Antimicrobial Agent Chemother.</i> 7:793, 1975		
C63	KIMURA Y et al., <i>J. Biochem.</i> , 116(5):991-994, 1994		
C64	KLOC, et al., "Interleukin-2 antisense oligonucleotides inhibit in vitro functions of T cells." <i>FASEB J.</i> , Vol. 5, pp. A973, abstract no. 3497, 1991.		
C65	KROWN, S.E., <i>Semin Oncol.</i> , 13(2):207-17, 1986		
C66	LEE, et al. <i>Transplantation</i> , 62:1297-1301, 1996		
C67	LEVINE, et al. <i>Cancer Treatment Repts.</i> 62:1907, 1978		
C68	LEVY, et al. <i>J Infect Disease</i> , 133:A256, 1976		
C69	LU, et al., <i>Clin. Exp. Immunol.</i> , 115:335-341, 1999		
C70	MACAYA, et al. <i>Proc Natl Acad Sci USA</i> 90:3745-9, 1993		
C71	MASHIBA, et al., <i>Jpn. J. Med. Sci. Biol.</i> , 41:197-202, 1988		
C72	MASTRANGELO, et al., <i>Seminars in Oncology</i> . 23(1):4-21, Feb 1996		
C73	MATSON S and KRIEG AM, <i>Antisense Res Dev</i> 2(4):325-30, Winter 1992		
C74	MATSUKURA, et al. <i>Proc Natl Acad Sci USA</i> 86:4244-48, 1989		
C75	MESSINA et al., <i>Cellular Immunology</i> , 147(1):148-157, 1993		
C76	NYCE and METZGER, <i>Nature</i> 385:721-725, 1997		
C77	PARKER, et al. <i>Cancer Gene Therapy</i> . 3:175, 1996		
C78	PETERSEN, et al., <i>Bio. Pharm.</i> , 47(1):127-128, 1994		
C79	PISETSKY DS, <i>Antisense Res Dev</i> , 5(3):219-225 (1995)		
C80	PISETSKY DS, <i>J Immunol</i> 156(2):421-3, 1996		
C81	POTTRATZ, et al., <i>J. Clin. Invest.</i> , 93(3):944-50, 1994		
C82	RAMANATHAN, et al. <i>J Biol Chem</i> 269:24565-74, 1994		
C83	RAMANATHAN, et al. <i>Transplantation</i> , 57:612-15, 1994		
C84	RAZ, et al., <i>Proc Natl Acad Sci USA</i> 93(10):5141-5, (1996)		
C85	ROMAN M et al., <i>Nat Med</i> 3(8):849-54, (1997)		
C86	ROUSH, et al. <i>Science</i> , 276:1193, 1997		
C87	SATO et al., <i>Science</i> , 273:352-354, 1996		
C88	SHIRAKAWA, et al., <i>Science</i> 275(5296):77-9, (1997)		
C89	SIN, et al, <i>J. of Virol.</i> , 73(1):501-509, 1999		
C90	SIN, et al., <i>J. of Immunol.</i> , 162:2912-2921, 1999		
C91	STULL et al., <i>Pharmaceutical Res.</i> , 12(4):465-483, 1995		
C92	TALMADGE, et al., <i>Cancer Res.</i> 45(3):1058-65, 1985		
C93	TSUJI, et al., <i>J. of Immunol.</i> , 158:4008-4013, 1997		
C94	WANG, et al. <i>Proc. Natl Acad. Sci. USA</i> , 90:4156-4160, 1993		
C95	WILTROUT, et al., <i>J. Biol. Res. Mod.</i> , 4(5):512-7, 1985		
C96	WYATT, et al. <i>Proc Natl Acad Sci USA</i> , 91:1356-60, 1994		

EXAMINER

DATE CONSIDERED

6/17/04

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]





RECEIVED

JUN 05 2001

FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: C1039/7035	TECH CENTER 4600/2800
	APPLICANT: Krieg, et al.	
	FILING DATE: September 25, 2000	GROUP: 1646

## U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate

## FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No

## OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

DB	C1	Kataoka, et al., "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG", <i>Jpn. J. Cancer Res.</i> , 83:244-247 (1992)
	C2	Krieg, et al., "Editorial: Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?", <i>Antisense Res. Devel.</i> , 5:241 (1995)
	C3	Krieg, A.M., "Leukocyte stimulation by oligodeoxynucleotides", <i>Applied Antisense Oligonucleotide Technology</i> , 24:431-448 (1998)
	C4	Sun, et al., "Mitogenicity of DNA from different organisms for murine B cells", <i>J. Immunol.</i> , 159:3119-3125 (1997)
	C5	Krieg, et al., "Brief Communication: Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs", <i>Antisense Nucleic Acid. Drug Development</i> , 6:133-139 (1996)
	C6	Messina, et al., "Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA", <i>J. of Immunol.</i> , 147(6):1759-1764 (1991)
	C7	McIntyre, et al., "A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kB p65 causes sequence-specific immune stimulation", <i>Antisense Res. and Devel.</i> , 3:309-322 (1993)
	C8	Hartmann, et al., "Mechanism and function of a newly identified CpG DNA motif in human primary b cells", <i>J. of Immunol.</i> , 164:944-952 (2000)
	C9	Yi, et al., "CpG DNA rescues B cells from apoptosis by activating NF-kB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway", <i>International Immunol.</i> , 11(12):2015-2024 (1999)
✓	C10	Hartmann, et al., "Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo", <i>J. of Immunol.</i> , 164:1617-1624 (2000)
DB	C11	Pisetsky, et al., "The influence of base sequence on the immunological properties of defined oligonucleotides", <i>Immunopharmacology</i> , 40:199-208 (1998)

536953.1

Paul Biele

6/17/04

